In plain English
How peptides are regulated
People buy a lot of peptides on the “gray market” and aren’t sure what that means. The tangle usually comes from mixing up four different questions. This page pulls them apart — in about two minutes.
Before anything else: these are four separate questions. A peptide can be a “yes” on one and a “no” on the next.
Can you get your hands on it right now.
Whether selling or using it that way is allowed.
Whether the FDA reviewed it and cleared it for a use.
Whether there’s real evidence it does what’s claimed, made to a known quality.
Most “is this okay?” confusion is really these four getting collapsed into one. The diagram below keeps them apart.
The whole map
The four worlds a peptide can live in
Approved drug
The FDA reviewed it and approved it for a specific use. Prescribed by a clinician, dispensed by a pharmacy.
Compounded
A pharmacy can mix it for a patient — if it clears a chain of gates. This lane is where most confusion lives.
- 1 Nominated for the compounding list
- 2 Sorted into Category 1 (may be compounded meanwhile) or Category 2 (safety concerns)
- 3 Advisory committee (PCAC) recommends — advice only
- 4 The FDA decides and writes the rule
- 5 Added to the 503A list → pharmacies may compound it
Dietary supplement
Sometimes sold on supplement shelves. But most peptides don’t legally qualify as dietary ingredients, so this is rarely a real home for them.
Gray-market “research chemical”
Sold labeled “for research only — not for human use.” No FDA oversight of what’s actually in the vial, its purity, or its dose.
The catch-all: where a peptide lands when it fits none of the above — or while it waits for the process.
Read this diagram as text ⌄
A peptide can exist in one of four worlds. Approved drug (legitimate): the FDA reviewed and approved it for a use — legal, proven, prescribed. Compounded (legitimate, case-by-case): a pharmacy may mix it only after it passes a chain of gates — nominated, sorted into Category 1 or 2, recommended by the PCAC advisory committee, decided on by the FDA through rulemaking, and finally added to the 503A list; legal to compound is not the same as FDA-approved. Dietary supplement (limited): rarely a legitimate home, because most peptides don’t qualify as dietary ingredients. Gray-market “research chemical” (caution): sold “not for human use,” with no oversight of identity, purity, or dose — the catch-all where a peptide lands when it fits nothing else or is still waiting. Separately, anti-doping (WADA) rules overlay all four.
Where people get tripped up
Three things that sound true but aren’t
Each of these mistakes a single step in the compounding lane for the finish line.
“It came off Category 2, so it’s legal now.”
Category 2 is a “possible safety risks” bucket, not a ban. Leaving it doesn’t make a peptide approved or legal — it just means one flag was cleared. The FDA still has to act.
“The PCAC committee decided, so it’s settled.”
PCAC only advises. Its recommendation is a signpost, not the destination. The FDA makes the call and has to write it into a rule before anything changes.
“It’s compounded, so it’s basically FDA-approved.”
Compounding is a separate lane. It lets a pharmacy prepare something for a patient — it does not mean the FDA studied and approved that peptide for effectiveness or safety.
The honest part
Many peptides will never finish the process — and that’s the whole gray market
Completing the path to “approved” takes a sponsor willing to fund years of trials. For a lot of peptides that never happens: no company stands to profit, the safety data stays thin, or a nomination gets withdrawn. So they sit in the gray market indefinitely — available, but never legal, proven, or quality-controlled.
What buying gray-market actually meansSo where does each peptide actually sit?
We mapped every compound in the library onto these worlds — filter by stage and jump straight to the entry.